Good morning :)
$
₹
Cytokinetics Inc

Cytokinetics Inc

CYTK

NASDAQ
Asset Logo

Cytokinetics Inc

CYTK

NASDAQ
$53.763.22% (-1.79)
$
₹
$53.763.22% (-1.79)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $8.8B the stock is ranked 1053

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

60.30
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-7.22
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

-0.42
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 23 analysts reports

Buy
21 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+93.32%

Earnings Growth

-6.43%

Rev. Growth

+79.67%

See Detailed Forecast

Company Profile

Company Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 93.32% growth, versus a trailing 3-year CAGR of 17.29%.

2026
Current$55.55Baseline
Analyst Target - 1 year
Target$107.39+93.32%

All values in $

202220232024202520262027$60.46$79.68$98.91Target+93.32%
2026
Current$55.55Baseline
Analyst Target - 1 year
Target$107.39+93.32%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 79.67% growth, versus a trailing 3-year CAGR of -2.36%.

2025
Current$88.03Baseline
Forecast for Dec 2026
High$216.03+145.39%
Average$158.18+79.67%
Low$133.78+51.96%

All values in $ Million

20212022202320242025202670.4294.587.5318.4788.03Low+51.96%Average+79.67%High+145.39%
2025
Current$88.03Baseline
Forecast for Dec 2026
High$216.03+145.39%
Average$158.18+79.67%
Low$133.78+51.96%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-5.52Baseline
Forecast for Dec 2026
High$-4.75+14.03%
Average$-5.88-6.43%
Low$-6.38-15.58%

All values in $

202120222023202420252026-2.83-3.98-5.45-5.26-5.52Low-15.58%Average-6.43%High+14.03%
2025
Current$-5.52Baseline
Forecast for Dec 2026
High$-4.75+14.03%
Average$-5.88-6.43%
Low$-6.38-15.58%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

17.7
-183
19.3
-206
31.9
-198.7
47.5
-190
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue0.240.4616.921.5766.761.9317.7519.3531.9147.55
Net Income-143.31-160.54-150.02-161.37-134.37-306.17-183.03-206.03-198.76-190.06
Net Profit Margin-57557.42%-34674.94%-886.27%-10220.13%-201.24%-15814.97%-1030.87%-1064.48%-622.80%-399.66%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Cytokinetics Inc -60.30-0.42
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CYTK with any stock or ETF
Compare CYTK with any stock or ETF
Comparing from
CYTK
ABBV
AMGN
Loading...

Frequently asked questions

  1. Cytokinetics Inc (CYTK) share price today is $53.76 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $56.44 and a day low of $53.58.

  2. Cytokinetics Inc stock trades on NASDAQ under the ticker symbol CYTK.

  3. Cytokinetics Inc's market capitalization is $8.84B as of November 7, 2026 at 2:29 AM IST.

  4. Cytokinetics Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Cytokinetics Inc's price-to-book (P/B) ratio is 60.30 as of November 6, 2026.

  6. Yes, You can buy Cytokinetics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Cytokinetics Inc shares in three steps: 1. Search Cytokinetics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Cytokinetics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Cytokinetics Inc (CYTK) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.186 shares at the current price of $53.76.

Loading...